Open AccessPB1890: ZANUBRUTINIB IN ACALABRUTINIB‐INTOLERANT PATIENTS (PTS) WITH B‐CELL MALIGNANCIES
Author(s) -
Shadman M.,
Flinn I. W.,
Kingsley E. C.,
Freeman B.,
Levy M. Y.,
Cultrera J.,
Farber C. M.,
Chaudhry A.,
Porter R.,
Crescenzo R.,
Idoine A.,
Zhang X.,
Cohen A.,
By K.,
Huang J.,
Sharman J. P.
Publication year - 2022
Publication title -
hemasphere
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.677
H-Index - 11
ISSN - 2572-9241
DOI - 10.1097/01.hs9.0000850412.41160.5d
Subject(s) - ibrutinib , tolerability , medicine , adverse effect , mantle cell lymphoma , diffuse large b cell lymphoma , phases of clinical research , oncology , lymphoma , pharmacology , chronic lymphocytic leukemia , clinical trial , leukemia